DK1503984T3 - 8-azaprostaglandin-analoger som midler til sænkning af intraokulært tryk - Google Patents

8-azaprostaglandin-analoger som midler til sænkning af intraokulært tryk

Info

Publication number
DK1503984T3
DK1503984T3 DK03724322.7T DK03724322T DK1503984T3 DK 1503984 T3 DK1503984 T3 DK 1503984T3 DK 03724322 T DK03724322 T DK 03724322T DK 1503984 T3 DK1503984 T3 DK 1503984T3
Authority
DK
Denmark
Prior art keywords
azaprostaglandin
analogues
agents
intraocular pressure
lowering intraocular
Prior art date
Application number
DK03724322.7T
Other languages
English (en)
Inventor
David W Old
Danny Thang Dinh
Robert M Burk
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK1503984T3 publication Critical patent/DK1503984T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
DK03724322.7T 2002-05-14 2003-04-28 8-azaprostaglandin-analoger som midler til sænkning af intraokulært tryk DK1503984T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/146,224 US6573294B1 (en) 2002-05-14 2002-05-14 8-azaprostaglandin analogs as agents for lowering intraocular pressure
PCT/US2003/013300 WO2003097596A1 (en) 2002-05-14 2003-04-28 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Publications (1)

Publication Number Publication Date
DK1503984T3 true DK1503984T3 (da) 2013-05-27

Family

ID=22516366

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03724322.7T DK1503984T3 (da) 2002-05-14 2003-04-28 8-azaprostaglandin-analoger som midler til sænkning af intraokulært tryk

Country Status (12)

Country Link
US (3) US6573294B1 (da)
EP (1) EP1503984B1 (da)
JP (3) JP2005530796A (da)
KR (1) KR20050000531A (da)
CN (1) CN1313447C (da)
AU (2) AU2003231188A1 (da)
BR (1) BR0310047A (da)
CA (1) CA2485850C (da)
DK (1) DK1503984T3 (da)
ES (1) ES2402764T3 (da)
MX (1) MXPA04011213A (da)
WO (1) WO2003097596A1 (da)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE281432T1 (de) 1999-03-05 2004-11-15 Univ Duke C-16 ungesätigte fp-selektive prostaglandin analoge
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
PT1339678E (pt) * 2000-11-27 2007-11-30 Pfizer Prod Inc Agonistas selectivos do receptor ep4 no tratamento de osteoporose
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
CA2466757A1 (en) * 2001-12-03 2003-06-12 Merck & Co., Inc. Method for treating ocular hypertension
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure
US7256211B1 (en) 2003-01-21 2007-08-14 Ono Pharmaceutical Co., Ltd. 8-azaprostaglandin derivatives and medical use thereof
US6734201B1 (en) * 2003-06-02 2004-05-11 Allergan, Inc. 8-Azaprostaglandin carbonate and thiocarbonate analogs as therapeutic agents
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
AU2005252171A1 (en) 2004-06-04 2005-12-22 Allergan, Inc. Piperidinyl prostaglandin analogs as ocular hypotensive agents
EP1812017A2 (en) * 2004-10-21 2007-08-01 Duke University Ophthamological drugs
EP1856042B1 (en) * 2005-03-10 2012-06-27 Allergan, Inc. Substituted gamma lactams as therapeutic agents
AU2012211448B2 (en) * 2005-03-10 2016-01-07 Allergan, Inc. Substituted gamma lactams as therapeutic agents
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
EP1996546B1 (en) * 2006-03-20 2014-11-26 Allergan, Inc. Substituted gamma lactams as prostaglandin ep2 agonists
US20070232660A1 (en) * 2006-04-04 2007-10-04 Allergan, Inc. Therapeutic and delivery methods of prostaglandin ep4 agonists
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US7553860B2 (en) * 2006-06-14 2009-06-30 Allergan, Inc. Substituted gamma lactams as therapeutic agents
ATE502914T1 (de) * 2006-08-09 2011-04-15 Allergan Inc Therapeutische amide und entsprechende verbindungen
CA2676291C (en) * 2007-01-31 2017-11-28 Allergan, Inc. Substituted gamma lactams as therapeutic agents
NZ598945A (en) * 2007-02-15 2013-08-30 Allergan Inc Gamma-lactams for the treatment of glaucoma or elevated intraocular pressure
US7956055B2 (en) * 2008-03-25 2011-06-07 Allergan, Inc. Substituted gamma lactams as therapeutic agents
UA103616C2 (ru) * 2008-04-24 2013-11-11 Аллерган, Инк. Замещенные гамма-лактамы как терапевтические агенты
US7985765B2 (en) * 2008-08-20 2011-07-26 Allergan, Inc. Therapeutic substituted pyrroles
US8623918B2 (en) 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
WO2012024072A1 (en) * 2010-08-19 2012-02-23 Allergan, Inc. Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition
CN107802623B (zh) 2012-07-19 2020-10-30 开曼化学股份有限公司 用于ep4介导的骨相关疾病和病症的二氟内酰胺组合物
WO2014144610A1 (en) 2013-03-15 2014-09-18 Cayman Chemical Company, Inc. Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
EP3235817B1 (en) 2013-03-15 2018-12-12 Cayman Chemical Company, Incorporated Lactam compounds as ep4 receptor-selective agonists for use in the treatment of ep4-mediated diseases and conditions
JP2016527006A (ja) 2013-07-19 2016-09-08 ケイマン ケミカル カンパニー， インコーポレーテッド 骨成長を促進するための方法、システム、及び組成物
WO2015140701A1 (en) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Azaindole acetic acid derivatives and their use as prostaglandin d2 receptor modulators

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2528664A1 (de) * 1975-06-27 1977-01-13 Hoechst Ag Pyrrolidone und verfahren zu ihrer herstellung
CA1077948A (en) * 1976-08-06 1980-05-20 Albin J. Nelson 1,-5 disubstituted-2-pyrrolidones and processes for their production
US4177346A (en) * 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
CA2021316C (en) 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US5028624A (en) 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
JP2000095755A (ja) * 1998-07-21 2000-04-04 Ono Pharmaceut Co Ltd ω―シクロアルキル―プロスタグランジンＥ１誘導体、その製造方法およびその誘導体を有効成分とする医薬組成物
WO2000038667A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of glaucoma
AP2001002357A0 (en) 1999-12-22 2001-12-31 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis.
DE60120007T2 (de) 2000-01-31 2006-11-16 Pfizer Products Inc., Groton Verwendung von Aktivatoren des Prostaglandinrezeptores 4 zur Behandlung von akuter oder chronischer Niereninsuffizienz
US20010056060A1 (en) 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists
WO2002024647A1 (en) 2000-09-21 2002-03-28 Ono Pharmaceutical Co., Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
PT1339678E (pt) 2000-11-27 2007-11-30 Pfizer Prod Inc Agonistas selectivos do receptor ep4 no tratamento de osteoporose
RU2296122C2 (ru) 2001-07-16 2007-03-27 Ф.Хоффманн-Ля Рош Аг Производные 2-пирролидона в качестве простаноидных агонистов и фармацевтическая композиция
ES2254726T3 (es) 2001-07-16 2006-06-16 F. Hoffmann-La Roche Ag Analogos de prostaglandina como agonistas receptores de ep4.
NZ530885A (en) 2001-07-23 2007-09-28 Ono Pharmaceutical Co Remedies for diseases with bone mass loss having EP4 agonist as the active ingredient
CA2466757A1 (en) * 2001-12-03 2003-06-12 Merck & Co., Inc. Method for treating ocular hypertension
BR0308493A (pt) * 2002-03-18 2005-01-11 Pfizer Prod Inc Uso de agonistas de receptor seletivo de ep4 para o tratamento da insuficiência hepática, perda de permeabilidade do canal arterial, glaucoma ou hipertensão ocular
CA2478653A1 (en) * 2002-03-18 2003-09-25 Pfizer Products Inc. Methods of treatment with selective ep4 receptor agonists
US6573294B1 (en) * 2002-05-14 2003-06-03 Allergan, Inc. 8-azaprostaglandin analogs as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
US20040157912A1 (en) 2004-08-12
WO2003097596A1 (en) 2003-11-27
KR20050000531A (ko) 2005-01-05
US6906097B2 (en) 2005-06-14
CA2485850C (en) 2012-07-03
JP2011116768A (ja) 2011-06-16
CA2485850A1 (en) 2003-11-27
MXPA04011213A (es) 2005-02-14
US6573294B1 (en) 2003-06-03
HK1072603A1 (en) 2005-09-02
AU2003231188A1 (en) 2003-12-02
EP1503984A1 (en) 2005-02-09
US20030220506A1 (en) 2003-11-27
JP2005530796A (ja) 2005-10-13
CN1313447C (zh) 2007-05-02
BR0310047A (pt) 2005-02-15
ES2402764T3 (es) 2013-05-08
CN1653045A (zh) 2005-08-10
EP1503984B1 (en) 2013-03-20
AU2010201226A1 (en) 2010-04-22
JP2014122250A (ja) 2014-07-03

Similar Documents

Publication Publication Date Title
DK1503984T3 (da) 8-azaprostaglandin-analoger som midler til sænkning af intraokulært tryk
DK2263674T3 (da) 10,10-Dialkyl-prostansyrederivater som midler til sænkning af intraokulært tryk
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
DK1575416T3 (da) Fremgangsmåder til diagnosticering af præeklampsi
NO20044174L (no) Kumariner som er nyttige som biomarkorer
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
DK1504126T3 (da) Fremgangsmåde til regulering af genekspression
NO20035775L (no) 3-fluor-pyrrolidiner som anti-diabetesmidler
DK1638928T3 (da) N-alkynyl-2-(substituerede aryloxy)alkylthio-amidderivater som fungicider
DK1414803T3 (da) Pyrazolylcarboxanilider som fungicider
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1487806T3 (da) 4-anilin-quinazolinderivater som antiproliferative midler
DK1423391T3 (da) Pyrrolopyrimidiner som midler til inhibering af cysteinproteaser
NO20053775D0 (no) Diazepinoindol derivater som kinaseinhibitorer.
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
DK1660090T3 (da) Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
NO20051688D0 (no) Farmasoytiske blandinger som har en modifisert baerer
NO20052884D0 (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
NO20033618L (no) Ftalayinon-piperidino-derivater som PDE-4-inhibitorer
DE60335913D1 (de) Ghrelin-analoga
DK1536685T3 (da) Fremgangsmåde til fremstilling af pasta-ekstruderede sulfonamidsammensætninger
NO20054669D0 (no) Substituerte kinobenzoxazinanaloger
DK1575948T3 (da) Pyridodiaziner som plantefungicider
NO20044092L (no) Oftalmisk sammensetning som innbefatter ascomycin